Opendata, web and dolomites


Disruptive GPCR Lead Discovery Platform Delivering New and Safer Therapeutics

Total Cost €


EC-Contrib. €






 PICARD project word cloud

Explore the words cloud of the PICARD project. It provides you a very rough idea of what is the project "PICARD" about.

disease    successfully    fee    pharmacologically    selective    lies    lowering    gpcrs    candidates    off    inefficiencies    biology    80    costly    play    break    stages    investment    human    price    variety    class    fail    paying    custom    functional    trials    service    screening    coupled    drugs    receptors    trial    reducing    vital    stream    milestone    fast    eth    discovery    market    detection    quality    drug    375    signalling    roi    protein    clinical    gpcr    45    efficacy    revenue    fte    mechanisms    diseases    upfront    combination    designed    swiss    profiles    paul    leaving    therapeutics    services    risks    platform    inflates    companies    payments    biological    cover    society    assays    earlier    commercialization    uuml    interax    outsourcing    reaching    activation    identification    pharmaceutical    compounds    implicated    gt    2b    estimate    efficient    time       5000    patients    scherrer    picard    central    safety    biotech    novelty    spin    nature    company   

Project "PICARD" data sheet

The following table provides information about the project.


Organization address
postcode: 5234
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INTERAX BIOTECH AG CH (VILLINGEN) coordinator 50˙000.00


 Project objective

InterAx Biotech, a Swiss company and spin-off from the ETH Zürich and the Paul Scherrer Institute has built PICARD, a unique drug discovery platform for the identification of drug candidates with improved efficacy and reduced side effects for the largest class of human receptors: The G-Protein Coupled Receptors (GPCRs). These receptors play a central role in many vital biological processes and they are implicated in a large variety of human diseases. Due to their complex nature and mechanisms that lead to the disease state, only 60 out of 375 pharmacologically relevant GPCRs have been successfully targeted by drugs, leaving >80% GPCRs without therapeutics. Bringing a drug to the market requires an investment of up to €2.2B; out of 5000 compounds only 5 will make it to the clinical trial phase and 9 out of 10 compounds fail during costly clinical trials. This inflates the price of the drugs that reach the patients, making the society paying for inefficiencies of pharmaceutical R&D. PICARD will enable better and earlier detection of safety and efficacy profiles of GPCR-targeting drugs by increasing quality and reducing costs and time-to-market of new therapeutics. The novelty of our discovery platform lies on the combination of our screening to find novel compounds, signalling Assays that cover the most common GPCR activation aspects and our Systems Biology approach leading to highly efficient and fast delivery of functional-selective compounds. We offer custom-designed PICARD services to pharmaceutical and biotech companies that are outsourcing key stages of their drug discovery process lowering risks and greatly reducing R&D costs. The revenue stream is generated both from fee per service and from long-term drug discovery partnerships with upfront and milestone payments. We estimate reaching break-even 2 years after commercialization with 45 FTE and achieving a ROI of 4.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

Presque (2019)

Smart Nursing Bra

Read More